A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and
ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.